Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed at $1.49 up 2.05% from its previous closing price of $1.46. In other words, the price has increased by $2.05 from its previous closing price. On the day, 0.63 million shares were traded. XFOR stock price reached its highest trading level at $1.51 during the session, while it also had its lowest trading level at $1.4.
Ratios:
For a deeper understanding of X4 Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.05 and its Current Ratio is at 3.19. In the meantime, Its Debt-to-Equity ratio is 19.65 whereas as Long-Term Debt/Eq ratio is at 19.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 16 ’25 when Baldry Mark bought 1,032 shares for $2.48 per share. The transaction valued at 2,561 led to the insider holds 25,337 shares of the business.
Baldry Mark bought 13,404 shares of XFOR for $4,598 on Nov 15 ’24. The Chief Commercial Officer now owns 129,173 shares after completing the transaction at $0.34 per share. On Jan 24 ’25, another insider, Ragan Paula, who serves as the President and CEO of the company, sold 76,473 shares for $0.45 each. As a result, the insider received 34,719 and left with 1,087,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 10696352 and an Enterprise Value of -284857. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 2.99. Its current Enterprise Value per Revenue stands at -0.009 whereas that against EBITDA is 0.003.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.54, which has changed by -0.9219078 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $26.83, while it has fallen to a 52-week low of $1.38. The 50-Day Moving Average of the stock is -34.16%, while the 200-Day Moving Average is calculated to be -84.42%.
Shares Statistics:
For the past three months, XFOR has traded an average of 839.00K shares per day and 1056340 over the past ten days. A total of 7.96M shares are outstanding, with a floating share count of 3.89M. Insiders hold about 32.74% of the company’s shares, while institutions hold 29.80% stake in the company. Shares short for XFOR as of 1752537600 were 390377 with a Short Ratio of 0.47, compared to 1749772800 on 484831. Therefore, it implies a Short% of Shares Outstanding of 390377 and a Short% of Float of 5.5.
Earnings Estimates
The current assessment of X4 Pharmaceuticals Inc (XFOR) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$2.69, with high estimates of -$1.09 and low estimates of -$3.69.
Analysts are recommending an EPS of between -$5.03 and -$12.78 for the fiscal current year, implying an average EPS of -$9.62. EPS for the following year is -$12.23, with 3.0 analysts recommending between -$3.28 and -$17.51.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $2.06M this quarter.It ranges from a high estimate of $2.4M to a low estimate of $1.75M. As of the current estimate, X4 Pharmaceuticals Inc’s year-ago sales were $560kFor the next quarter, 5 analysts are estimating revenue of $2.61M. There is a high estimate of $3.7M for the next quarter, whereas the lowest estimate is $1.93M.
A total of 5 analysts have provided revenue estimates for XFOR’s current fiscal year. The highest revenue estimate was $36.5M, while the lowest revenue estimate was $33.95M, resulting in an average revenue estimate of $35.11M. In the same quarter a year ago, actual revenue was $2.56MBased on 6 analysts’ estimates, the company’s revenue will be $22.83M in the next fiscal year. The high estimate is $34.2M and the low estimate is $10.3M.
